Cassava Sciences, Inc.

NasdaqCM SAVA

Cassava Sciences, Inc. Return on Capital Employed (ROCE) for the Trailing 12 Months (TTM) ending September 30, 2024

Cassava Sciences, Inc. Return on Capital Employed (ROCE) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqCM: SAVA

Cassava Sciences, Inc.

CEO	Mr. Richard Jon Barry
IPO Date	July 14, 2000
Location	United States
Headquarters	7801 North Capital of Texas Highway
Employees	29
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Key trends

Past 5 years